Boceprevir/Peginterferon Alfa (PegIFN alpha)-2b/Ribavirin (Riba) in Difficult-to-Treat Menopausal Women With Chronic Hepatitis C Genotype 1 (Gt 1), Either Deemed Nonresponders to Peginterferon/Ribavirin or Treatment-naives (MEN_BOC)
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 30 Mar 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2011-002459-33).
- 01 Nov 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 26 Oct 2011 New trial record